We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Sciences’ Yescarta Shows Favorable Results Just After BMS’ Rival CAR-T Therapy Performed Well
Gilead Sciences’ Yescarta Shows Favorable Results Just After BMS’ Rival CAR-T Therapy Performed Well
Yescarta, Gilead Sciences’ CAR-T cell therapy for large B-cell lymphoma, is performing well in its phase 3 trial, news that came soon after Bristol Myers Squibb said its rival CAR-T cell therapy was performing favorably in its phase 3 trial.